PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial

Oriana Nanni¹*, Pierluigi Viale², Bernadette Vertogen¹, Claudia Lilli¹, Chiara Zingaretti¹, Caterina Donati¹, Carla Masini¹, Manuela Monti¹, Patrizia Serra¹, Roberto Vespignani¹, Veruska Grossi¹, Annibale Biggeri³, Emanuela Scarpi¹, Francesca Galardi¹, Lucia Bertoni¹, Americo Colamartini¹, Fabio Falcini¹, Mattia Altini¹, Ilaria Massa¹, Raffaella Gaggeri¹ and Giovanni Martinelli¹

Abstract

Objectives: Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation of viral surface proteins. In addition to its antiviral activity, hydroxychloroquine has an immune-modulating activity that may synergistically enhance its antiviral effect in vivo, making it a potentially promising drug for the prevention and the cure of SARS-CoV-19. However, randomized controlled trials are needed to assess whether it can be used safely to treat COVID-19 patients or to prevent infection. The main objective of the present study is to evaluate the efficacy of hydroxychloroquine for (I) the prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients.

Trial design: This is a controlled, open label, cluster-randomized, superiority trial with parallel group design. Subjects will be randomized either to receive hydroxychloroquine or to observation (2:1).

(Continued on next page)
Participants: SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled. Paucisymptomatic patients are defined as patients with a low number of mild symptoms. All subjects must be aged ≥18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (in-tolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation).

The study is monocentric and will be conducted at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Subjects will be enrolled from a large epidemic region (North-Central Italy). The Public Health Departments of several Italian regions will collaborate by identifying potentially eligible subjects.

Intervention and comparator: The participants will be randomized (2:1 randomization) to receive either hydroxychloroquine (Arm A) or to Observation (Arm B). Hydroxychloroquine will be administered with the following schedule:

Group 1: A loading dose hydroxychloroquine 400 mg twice daily on day 1, followed by a weekly dose of hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, for a total of one month of treatment.

Group 2: A loading dose hydroxychloroquine 400 mg twice daily on day 1 followed by 200 mg twice daily for a total of 5-7 days.

The comparator in this trial is observation given that currently neither treatment is administered to asymptomatic or paucisymptomatic subjects, nor prophylaxis is available for contacts.

Hydroxychloroquine will be shipped to subjects within 24 hours of randomization. Given the extraordinary nature of the COVID-19 pandemic, only telephonic interviews will be carried out and electronic Patient Reported Outcomes (ePRO) completed. During treatment, each subject will be contacted every other day for the first week and weekly thereafter (Group 2) or weekly (Group 1) by a study physician to assess early onset of any COVID-19 symptom or any adverse reaction to hydroxychloroquine and to check subject compliance. Furthermore, all subjects will receive periodic ePROs which may be completed through smartphone or tablets to record drug self-administration and onset of any symptom or adverse event. All subjects will be followed up for a total of 6 months by periodic telephonic interviews and ePROs.

Main outcomes: The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization.

Randomization: All household members and/or contacts of each COVID-19 index case, and the COVID-19 patient himself/herself, fulfilling all inclusion criteria will be grouped into a single cluster and this cluster will be randomized (2:1) to either arm A or arm B. Information on each subject will be recorded in specific data records. Randomization lists will be stratified according to the following factors regarding COVID-19 index cases:

1. COVID-19 risk level on the basis of province of residence (high vs. low/intermediate);
2. Index case is a healthcare professional (yes vs. no)
3. Index case with COVID-19 treatment (yes vs. no)

An independent statistician not otherwise involved in the trial will generate the allocation sequence, and COVID-19 response teams will be unaware of the allocation of clusters.

Randomization will be performed through an interactive web-based electronic data-capturing database. An Independent Data Monitoring Committee has been established.

Blinding (masking): This study is open label.

(Continued on next page)
Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-020-04527-4.

Additional file 1. Full Study Protocol.
Additional file 2. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Acknowledgements

We wish to acknowledge the PROTECT Investigators and Staff: Caterina Florescu, Valentina Fausti, Laura Matteucci, Pier Paolo Fattori, Alberto Bongiovanni, Alessandro Passardi, Nazario Teodorani, Pietro Cortesi, Irene Marini, Francesco Limarzi, Chiara Pazzi, Lorena Rossi, Martina Valigiusti, Giovanni Luca Frassinetti, Ilario Giovanni Rapposelli, Valentina Masoni, Francesco Mazza, Andrea Zaccheroni and Emanuele Zavoli.
We also thank the members of the Independent Data Monitoring Committee: Alessandra Gennari, Antonello Di Paolo and Federico Pea. Finally, our thanks go to the Public Health Departments of Forlì, Cesena, Rimini, Ravenna, Ferrara, Imola, Bologna, Reggio Emilia, Piacenza, Parma, Modena, Alessandria, Verona, Aosta, and Novara for providing us on a daily basis with potential trial subject lists.

Authors’ contributions

G.M., P.V., O.N., A.B and M.A., were responsible for the study concept and trial design. B.V., C.L., C.Z., C.D., C.M., E.S., R.G., M.M., P.S and R.V. contributed to the study protocol drafting the final version of the protocol. All authors read and approved the present version of the manuscript for submission.

Funding

IRST IRCCS is funding this trial and will have full oversight of the design of the study, collection, analysis, and interpretation of data and drafting of the manuscript.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

On 20th April 2020 this trial received the approval of the Ethics Committee (EC) of Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani-IRCCS, which is the national EC for COVID-19 trials. Informed consent will be obtained from participants prior to involvement in the trial. Given the extraordinary nature of the pandemic diffusion of COVID-19 and the safety measures set up to contain the spread of infection, it is not feasible to provide information to potentially eligible subjects through a face-to-face interview or to obtain informed consent signed in person by the subjects. Therefore, subjects will receive detailed information through a telephonic interview with a suitably qualified and experienced study physician and will then provide their consent through a web-based application. Written information about the study and informed consent forms will be made available through the study website. Whenever possible, a signed informed consent form will be obtained from subjects.

IRST IRCCS, Meldola, Italy is the sponsor of this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
Author details
1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. 2Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. 3Dipartimento di Statistica, Informatica, Applicazioni “G. Parenti” (DISIA), Università degli studi Firenze, Florence, Italy.

Received: 15 June 2020 Accepted: 16 June 2020
Published online: 31 July 2020

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.